Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Benefit from High Preference to Chemotherapy Cancer Treatments in Developing Economies

Published Date : Mar 29, 2017

Albany, New York, March 29, 2017: A recent report added to the vast research report portfolio of presents a detailed overview of the present state of development and growth prospects over the period between 2017 and 2021 of the global chemotherapy-induced nausea and vomiting (CINV) drugs market. The report titled “Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021,” states that the market will exhibit a promising 6% CAGR over the said period. 

The rising preference to chemotherapy to treat a variety of cancers, especially in developing economies such as India and China, and the resultant rise in the prevalence of chemotherapy-induced nausea and vomiting is considered the key factor expected to drive the market in the near future. The low popularity of targeted therapy is also expected to contribute to the increased preference to chemotherapy in these countries, driving the market for CINV drugs. 

The market has been segmented on the basis of therapy into NK1 receptor antagonists and serotonin receptor antagonists. Of these, the segment of serotonin receptor antagonists dominated in 2016, accounting for a leading share in the global market. These drugs operate by blocking the binding of serotonin to its receptor, which help in stopping the signals of vomit-stimulating from being transmitted to the brain. Some of the commonly used serotonin antagonist drugs in the global market are Palonosetron, Ondansetron, Tropisetron, Dolasetron, and Granisetron. 

From a geographical point of view, the report includes detailed reports of the market for CINV drugs across Americas (North America and South America), APAC (Asia Pacific), and EMEA (Europe, Middle East and Africa). Of these, the report states that the market in Americas will be the key contributor of revenue to the global market throughout the forecast period. The massive rise in prevalence of cancer in the U.S. will lead to an increased number of patients undergoing chemotherapy, leading to the increased need for CINV drugs. The Americas CINV drugs market will also benefit from the rising R&D activities aimed at the development of new varieties of antiemetics. 

For Sample Copy, click here: 

The global CINV drug market features a highly fragmented vendor landscape owing to the presence of a large number of companies. Companies compete in terms of prolonged action of the drug, its efficacy, rich pipeline, and limited side effects. Companies are focusing on increasing their sales through strategies such as direct sales. The market is expected to become further competitive on account of the rise in R&D activities and the introduction of novel therapies. 

Some of the leading vendors operating in the market are GlaxoSmithKline, Heron Therapeutics, Helsinn, Tesaro, Merck, Especificos Stendhal, Acacia Pharma, Dr. Reddy's Laboratories, Lee’s Pharmaceutical Holdings, Aphios, Baxter Healthcare, Ono Pharmaceutical, Orchid Chemicals & Pharmaceuticals, F. Hoffmann-La Roche, Eisai, Purdue Pharma, Kyowa Hakko Kirin, SciClone Pharmaceuticals, Midatech Pharma, Mylan, OPKO Health, Otsuka Pharmaceutical, Specialised Therapeutics, Mundipharma, Solasia Pharma K.K., Teva Pharmaceuticals, Shin Nippon Biomedical Laboratories, Sun Pharma, and Taiho Pharmaceutical. 

To order report Call Toll Free: 866-997-4948 or send an email on